resTORbio Appoints Lloyd Klickstein, M.D., Ph.D., as Chief Scientific Officer
14 Maio 2019 - 9:00AM
resTORbio, Inc. (Nasdaq: TORC), a clinical-stage biopharmaceutical
company developing innovative medicines that target the biology of
aging to prevent or treat aging-related diseases, today announced
the appointment of Lloyd Klickstein, M.D., Ph.D., as Chief
Scientific Officer.
“We are honored to have Lloyd join the executive team at
resTORbio,” said Chen Schor, Co-Founder, President and CEO of
resTORbio. “Lloyd is an exceptional physician scientist with vast
experience in drug discovery and clinical development across a
range of aging-related indications. We look forward to Lloyd’s
leadership as we evaluate RTB101 in additional diseases of aging,
broaden our pipeline to study other TORC1 inhibitors, and bring
forward additional clinical candidates that target other aging
pathways.”
Dr. Klickstein brings to resTORbio a strong background in drug
discovery and development for new clinical indications with high
unmet medical need. Prior to joining resTORbio, Dr. Klickstein was
the Global Head of Translational Medicine for the New Indication
Discovery Unit and the Exploratory Disease Area at Novartis
Institutes for Biomedical Research, where he led teams that brought
forward multiple innovative programs in a wide array of therapeutic
areas including the research and development of small molecules for
nonalcoholic steatohepatitis, gene therapy for hearing loss, gene
editing for sickle cell anemia, and TORC1 inhibitors for diseases
of aging. Before Novartis, Dr. Klickstein was an academic
physician-scientist at Brigham and Women’s Hospital (BWH), where he
directed a basic research laboratory funded by the National
Institutes of Health and maintained an active clinical practice in
the Arthritis Center. Dr. Klickstein received a B.S. from Tufts
University and an M.D. and Ph.D. from Harvard University. He
completed post-graduate clinical training in Internal Medicine,
Rheumatology & Immunology at BWH and a post-doctoral research
fellowship at the Center for Blood Research in Boston, MA.
“I am eager to join resTORbio at such an exciting time for the
Company and the broader field of aging,” said Dr. Klickstein. “To
date, substantial preclinical evidence has identified biological
mechanisms that regulate the aging process, including the TORC1
pathway, and these data support the potential benefit of TORC1
inhibition for improving the function of aging organ systems. I
look forward to working with the team to further harness the
biology of aging to create new clinical candidates, as well as to
advance the ongoing clinical programs for RTB101 in improving
immune and neurologic
function.”
About resTORbioresTORbio, Inc. is a clinical-stage
biopharmaceutical company developing innovative medicines that
target the biology of aging to prevent or treat aging-related
diseases. resTORbio’s lead program selectively inhibits TORC1, an
evolutionarily conserved pathway that contributes to the decline in
function of multiple organ systems, including the immune,
cardiovascular and central nervous systems. Learn more about
resTORbio, Inc. at www.resTORbio.com.
Forward-Looking Statements
This press release contains forward-looking statements within
the meaning of the Private Securities Litigation Reform Act of
1995, as amended. Investors are cautioned that statements in this
press release which are not strictly historical statements,
including, without limitation, express or implied statements or
guidance regarding our growth as a company and the
anticipated contribution of our executives to our operations and
progress, our proposed timing and trial design for our PROTECTOR
Phase 3 clinical program of RTB101, including timing and
anticipated results of this clinical trial, our future plans to
develop RTB101 alone or in combination with rapalogs, such as
everolimus or sirolimus, including the therapeutic potential and
clinical benefits thereof and the potential patient populations
that may be addressed by our product candidates, our ongoing and
future clinical trials for RTB101, including the timing of the
initiation and anticipated results of these trials, the continued
expansion of our pipeline into Parkinson’s disease and UTIs, the
intended regulatory path for our product candidates and
interactions with regulatory authorities, our ability to replicate
results achieved in our clinical trials in any future trials, and
our cash position and expected cash runway, and our ability to fund
operations through 2020 constitute forward-looking statements
identified by words like “believe,” “expect,” “may,” “will,”
“should,” “seek,” “anticipate,” or “could” and similar
expressions.
Such forward-looking statements are subject to a number of risks
and uncertainties that could cause actual results to differ
materially from those anticipated, including, without limitation,
risks associated with: our PROTECTOR Phase 3 program; our planned
Phase 3 clinical trials in RTIs and/or development of RTB101,
either alone or in combination with a rapalog, such as everolimus
or sirolimus; our ability to successfully demonstrate the efficacy
and safety of our lead product candidate; the clinical results for
our lead product candidate which may not support further
development of additional indications; uncertainties related to the
results of our clinical trials predictive of future results in
connection with future trials, including our Phase 3 clinical
trials; the timing and outcome of our planned interactions with
regulatory authorities; and obtaining, maintaining and protecting
our intellectual property; as well as those risks more fully
discussed in the section entitled “Risk Factors” in the Annual
Report on Form 10-K filed by resTORbio, Inc. with
the Securities and Exchange Commission, as well as discussions
of potential risks, uncertainties, and other important factors in
our subsequent filings with the Securities and Exchange
Commission. In addition, any forward-looking statements
represent our views only as of today and should not be relied upon
as representing its views as of any subsequent date. resTORbio
explicitly disclaims any obligation to update any forward-looking
statements.
Investor ContactMichael SchaffzinStern Investor
Relations, Inc.212-362-1200michael.schaffzin@sternir.com
Media ContactAmir KhanBiosector
2212-462-8767Amir.Khan@Syneoshealth.com
resTORbio (NASDAQ:TORC)
Gráfico Histórico do Ativo
De Abr 2024 até Mai 2024
resTORbio (NASDAQ:TORC)
Gráfico Histórico do Ativo
De Mai 2023 até Mai 2024